FOXO3 and colitis: Research has demonstrated that a mixture of supernatants containing seven SCFAs promotes an anti-inflammatory macrophage phenotype in the colon by inhibiting the Janus Kinase-Forkhead box O3 signaling pathway, which leads to improved intestinal inflammation and enhanced barrier function in mice with DSS-induced colitis (54).